Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Weill Medical College of Cornell University: Clinical Trials & FDA Approval Profile

Weill Medical College of Cornell University (Global / Institutional) sponsors 75 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 40 active protocols (23 recruiting now), 14 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)28.0%
Median Closed Enrollment vs National (145 pts)24 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Weill Medical College of Cornell University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)75
Active Pipeline (Recruiting Now)40 (23)
Completed vs Stopped Early14 / 21 (28.0%)
Median Closed Actual Enrollment24 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Weill Medical College of Cornell University
Hospital Research SiteLocationShared Protocols
Weill Cornell MedicineNew York, NY65
Ohio State University Comprehensive Cancer CenterColumbus, OH5
Columbia University Irving Medical CenterNew York, NY5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Weill Medical College of Cornell University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03804944Converting HR+ Breast Cancer Into an Individualized VaccinePhase IIRECRUITING
NCT06994442Optimizing Pain Treatment in Children On Mechanical VentilationPhase IIIRECRUITING
NCT05997693One-Month DAPT in CABG PatientsPhase IIIRECRUITING
NCT06399705REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - MinoritiesPhase IIIRECRUITING
NCT06399692REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - WomenPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Weill Medical College of Cornell University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI